Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALTABAX vs BACIGUENT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Retapamulin is a pleuromutilin antibiotic that selectively inhibits bacterial protein synthesis by interacting with the 50S ribosomal subunit, specifically at the L3 ribosomal protein and the peptidyl transferase center, thereby preventing peptide bond formation.
Bacitracin inhibits bacterial cell wall synthesis by dephosphorylating the lipid carrier that transports peptidoglycan precursors across the cell membrane, leading to accumulation of toxic intermediates and cell lysis.
FDA-approved for topical treatment of impetigo due to Staphylococcus aureus and Streptococcus pyogenes in patients aged 9 months and older
Topical treatment of superficial skin infections caused by susceptible strains of Staphylococcus spp., Streptococcus spp., and other gram-positive bacteria,Prophylaxis of minor skin infections,Off-label: Prevention of infection in minor cuts, scrapes, and burns
1% ointment applied topically to affected area twice daily for 5 days. Total treatment area should not exceed 100 cm². Maximum single dose is 0.5 g per 100 cm².
Topical: Apply thin layer to affected area 1 to 3 times daily; maximum duration of therapy is 1 week.
Terminal half-life is approximately 11-14 hours in adults after topical application, supporting twice-daily dosing.
Terminal elimination half-life approximately 2.5–3.5 hours in adults with normal renal function; prolonged in renal impairment (up to 20–30 hours in anuria)
Retapamulin undergoes hepatic metabolism primarily via cytochrome P450 (CYP) isoenzymes, including CYP3A4, and is excreted in feces and urine.
Bacitracin undergoes minimal systemic absorption via topical application; not significantly metabolized; excreted unchanged in urine if absorbed.
Retapamulin is primarily eliminated via the fecal route (96.5% of dose), with minimal renal excretion (<0.5% of dose).
Primarily renal excretion of unchanged drug via glomerular filtration and tubular secretion; >90% of absorbed dose recovered in urine within 24 hours; biliary/fecal elimination minimal (<2%)
Retapamulin is approximately 94% bound to human plasma proteins, primarily albumin.
Approximately 20–30% bound to serum proteins, mainly albumin
Volume of distribution after IV administration is approximately 3.1 L/kg, indicating extensive tissue distribution.
0.25–0.4 L/kg (total body water); limited tissue distribution, primarily extracellular fluid
Systemic bioavailability after topical application is low and highly variable, with mean values <2% in adults.
Topical: negligible systemic absorption (<0.5%) through intact skin; oral: not absorbed (inactivated in GI tract; not used systemically)
No dose adjustment required for renal impairment as systemic absorption is negligible.
No dose adjustment required for topical use; systemic absorption is minimal.
No dose adjustment required for hepatic impairment as systemic absorption is negligible.
No dose adjustment required for topical use.
Children 9 months and older: Apply 1% ointment to affected area twice daily for 5 days. Maximum treatment area 100 cm². For children under 9 months: safety and efficacy not established.
Apply thin layer to affected area 1 to 3 times daily; safety in infants under 2 months not established.
No specific dose adjustment required. Use same as adult dosing due to minimal systemic absorption.
No specific dose adjustment; use same as adult dosing.
No black box warnings.
Due to nephrotoxicity, bacitracin is NOT recommended for parenteral use; topical use only.
Not for use on mucous membranes (e.g., eyes, mouth, vagina).,May cause application site reactions (e.g., pruritus, erythema, pain).,Clostridium difficile-associated diarrhea (CDAD) has been reported with nearly all antibacterial agents, including retapamulin.,Prolonged use may result in overgrowth of nonsusceptible organisms.
Hypersensitivity reactions including anaphylaxis,Prolonged use may result in overgrowth of non-susceptible organisms, including fungi,Avoid contact with eyes,Not for use on deep wounds or severe burns
Hypersensitivity to retapamulin or any component of the formulation.
Hypersensitivity to bacitracin or any component of the formulation
None known. Topical application with negligible systemic absorption; no dietary restrictions.
No known food interactions with topical bacitracin. Avoid ingestion.
No adequate and well-controlled studies in pregnant women. Animal studies: oral doses up to 50 mg/kg/day in rats (0.8 times MRHD based on AUC) and 40 mg/kg/day in rabbits (1.6 times MRHD) showed no fetal harm. However, systemic absorption after topical application is minimal, so fetal exposure is negligible. Risk cannot be ruled out; classify as pregnancy category B.
Bacitracin is not systemically absorbed from topical application, so fetal exposure is negligible. No known teratogenic risk in any trimester; however, systemic use (IM) is contraindicated due to nephrotoxicity, and limited data exist for systemic use in pregnancy. Animal studies show no evidence of harm, but human data are insufficient.
Not known if retapamulin is excreted in human milk. Systemic absorption is negligible after topical use, so risk to infant is likely low. M/P ratio not determined. Caution if applied to breast area to avoid infant ingestion.
Bacitracin is not systemically absorbed from topical use; therefore, breast milk exposure is negligible. M/P ratio is not applicable. Considered safe during breastfeeding when used topically. For systemic use, avoid due to potential nephrotoxicity.
No dose adjustment needed. Pharmacokinetics unchanged as systemic absorption is minimal (<1%) and not affected by pregnancy. Standard dosing: apply thin layer to affected area twice daily for 5 days.
No dosing adjustment needed for topical bacitracin. Systemic use is contraindicated in pregnancy due to risk of maternal nephrotoxicity; if unavoidable, use with extreme caution and monitor renal function, but no specific dose recommendations exist.
Retapamulin (Altabax) is a topical pleuromutilin antibiotic indicated for impetigo due to S. aureus or S. pyogenes. Apply to lesions twice daily for 5 days. Avoid contact with eyes, mouth, or mucous membranes. No systemic absorption significant; safe for use in children ≥9 months. Do not use on open wounds or burns. Monitor for local irritation; discontinue if hypersensitivity occurs.
Bacitracin is a topical polypeptide antibiotic effective against gram-positive organisms. It is often combined with neomycin and polymyxin B in triple antibiotic ointments. For minor wounds, apply a thin layer 1-3 times daily. Avoid use on large body surface areas or for deep puncture wounds due to risk of systemic absorption and nephrotoxicity. Monitor for allergic contact dermatitis, especially with prolonged use.
Apply a thin layer to the affected area twice daily for 5 days, even if symptoms improve.,Wash hands before and after application unless treating hand lesions.,Do not cover the area with bandages unless instructed by your doctor.,Avoid getting the ointment in your eyes, nose, mouth, or on vaginal area.,Stop use and inform your doctor if you develop severe irritation, redness, or swelling.,Store at room temperature away from heat and moisture.
Clean the affected area before each application.,Apply a thin layer of ointment 1 to 3 times daily.,Do not use on large areas of the body, deep wounds, or animal bites.,Stop use and consult a doctor if the condition worsens or does not improve within 1 week.,Avoid contact with eyes or mucous membranes.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALTABAX vs BACIGUENT, answered by our medical review team.
ALTABAX is a Topical Antibiotic that works by Retapamulin is a pleuromutilin antibiotic that selectively inhibits bacterial protein synthesis by interacting with the 50S ribosomal subunit, specifically at the L3 ribosomal protein and the peptidyl transferase center, thereby preventing peptide bond formation.. BACIGUENT is a Topical Antibiotic that works by Bacitracin inhibits bacterial cell wall synthesis by dephosphorylating the lipid carrier that transports peptidoglycan precursors across the cell membrane, leading to accumulation of toxic intermediates and cell lysis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALTABAX and BACIGUENT depend on the specific clinical indication. These are both Topical Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALTABAX is: 1% ointment applied topically to affected area twice daily for 5 days. Total treatment area should not exceed 100 cm². Maximum single dose is 0.5 g per 100 cm².. The standard adult dose of BACIGUENT is: Topical: Apply thin layer to affected area 1 to 3 times daily; maximum duration of therapy is 1 week.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALTABAX and BACIGUENT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALTABAX is classified as Category C. No adequate and well-controlled studies in pregnant women. Animal studies: oral doses up to 50 mg/kg/day in rats (0.8 times MRHD based on AUC) and 40 mg/kg/day in rabbits (1.6 time. BACIGUENT is classified as Category C. Bacitracin is not systemically absorbed from topical application, so fetal exposure is negligible. No known teratogenic risk in any trimester; however, systemic use (IM) is contrai. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.